Literature DB >> 22623121

The Treatment experience, burden, and unmet needs (TRIBUNE) study - measuring the socioeconomic consequences of Multiple Sclerosis.

Giovanni Fattore, Michael Lang, Maura Pugliatti.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22623121     DOI： 10.1177/1352458512447262

Source DB:  PubMed          Journal:  Mult Scler        ISSN： 1352-4585            Impact factor:   6.312


× No keyword cloud information.
  4 in total

1.  The impact of socioeconomic status on subsequent neurological outcomes in multiple sclerosis.

Authors:  Devi Sai Sri Kavya Boorgu; Shruthi Venkatesh; Chirag M Lakhani; Elizabeth Walker; Ines M Aguerre; Claire Riley; Chirag J Patel; Philip L De Jager; Zongqi Xia
Journal:  Mult Scler Relat Disord       Date:  2022-06-24       Impact factor: 4.808

2.  Types of working-life sequences among people recently diagnosed with multiple sclerosis in Sweden: a nationwide register-based cohort study.

Authors:  Chantelle Murley; Petter Tinghög; Korinna Karampampa; Jan Hillert; Kristina Alexanderson; Emilie Friberg
Journal:  BMJ Open       Date:  2020-12-29       Impact factor: 2.692

3.  Trajectories of disposable income among people of working ages diagnosed with multiple sclerosis: a nationwide register-based cohort study in Sweden 7 years before to 4 years after diagnosis with a population-based reference group.

Authors:  Chantelle Murley; Olof Mogard; Michael Wiberg; Kristina Alexanderson; Korinna Karampampa; Emilie Friberg; Petter Tinghög
Journal:  BMJ Open       Date:  2018-05-09       Impact factor: 2.692

4.  Evobrutinib, a covalent Bruton's tyrosine kinase inhibitor: Mass balance, elimination route, and metabolism in healthy participants.

Authors:  Holger Scheible; Martin Dyroff; Annick Seithel-Keuth; Eleanor Harrison-Moench; Nadra Mammasse; Andreas Port; Angelika Bachmann; Jennifer Dong; Jan Jaap van Lier; William Tracewell; David Mitchell
Journal:  Clin Transl Sci       Date:  2021-08-10       Impact factor: 4.689
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.